Κατεύθυνση Ανάπτυξη Νέων Φαρμάκων: Έρευνα, Κυκλοφορία και Πρόσβαση
Library of the School of Health Sciences

2024-04-13

2024

Mandraki Konstantina

Κωνσταντίνος Ν. Συρίγος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Γεώργιος Στεργίου, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ηλίας Κοττέας, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ

Η χρήση των συζευγμένων αντισωμάτων - φαρμάκων

Greek

The use of antibody-drug conjugates

This review is a complete presentation of approved Antibody-Drug Conjugates (ADCs). The building blocks of an antibody-drug conjugate are the monoclonal antibody (mAb), the drug/active substance that forms the payload or warhead, and the linker that conjugates the antibody to the drug. The conjugation occurs through a chemical compound, which must create a stable molecule, but not aggregated, so that when it reaches the target antigen, it can release the drug. The conjugation occurs through a chemical reaction, which must create a stable molecule, but not aggregated, so that when it reaches the target antigen, it can release the drug. The drug is a cytotoxic agent, which stops the proliferation of target cells or causes them to undergo apoptosis. The main features of today's clinically active ADCs are summarized below, referring to their approval date, their route of administration, their route of action, their composition, the disease they target, their therapeutic properties as well as their side effects. Recent clinical data are presented illustrating the benefit of targeting cancer cells, using antibodies, and delivering cytotoxic agents directly to cancer cells. The first ADC was approved by the US national drug agency (FDA) in 2001, but was voluntarily recalled in 2010 by the manufacturing company, due to the inability to demonstrate clinical benefit and a lower rate of toxicity compared to classical chemotherapy methods. It was approved again in 2017 and since then, by the end of 2023, a total of 16 ADCs have been approved, of which 13 are approved by the FDA (the 14th was withdrawn and is only approved by the EMA), 1 is only approved by China (NPMA) and 1 only by Japan (PMDA). There are over 150 new ADCs currently in clinical trials. Of these, ~12% are in the late phase (Phase III/IV) due to the rapid advances in technology required to produce ADCs. The goal is to reduce toxicity and increase selectivity and efficacy to refine and form the means for complete control of cancer treatment. 

Health Sciences

Immunotherapy, Chemotherapeutic, Monoclonal antibody, Tumor, Drug delivery, Targeting , Antibody conjugate, Oncology drug, Pharmacology, Drug development, Linker, Antigen, Warhead

No

0

Yes

44

132

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/3396236